The reason to differentiate de novo AML is based upon its difference in genetic and molecular nature that poses high risk other than BCR/ABL1+ gene only, treatment modality, and response from CML.1, 2, 3, 4. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.